Veszelei, I, Godman, B, Aaltonen, K, Selke, GW, Garuoliene, K, Cangini, A, Kurdi, A, Rodrigues, AT, Pontes, C, Torre, C, Lunghi, C, Burton, E, Poplavska, E, Jónsdóttir, F, Petrova, G, Langner, I, Iaru, I, Odnoletkova, I, Slaby, J, Gvozdanovic, K, Saastamoinen, L, Laius, O, Benkö, R, Ziogaite, S, McTaggart, S, Mueller, T, de Pando, T, Tesar, T, Mitkova, Z, Wettermark, B. Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability. BIODRUGS. 2025; 39(5)DOI:10.1007/s40259-025-00732-2. PMID:40779010. IF:6.900(Q1/1D).

Gawron, LP, Garrido-Ribas, I, Amaro-Carriba, MA, Hernández-Molina, M, Carceller-Sindreu, M, Carmona-Farrés, C, Portella, MJ, Pousa, E. Dimensions of insight in eating disorders: clinical and psychological predictors. PSYCHIATRY RESEARCH. 2025; 351DOI:10.1016/j.psychres.2025.116566. PMID:40482577. IF:3.900(Q1/2D).

Gawron, LP, Clifford, KR, Guillén, AR, Carceller-Sindreu, M, Farrés, CC, Bonnin, CD, Portella, MJ. Adapting Barlow's Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Overweight Adults: A Nonrandomized Controlled Feasibility Study. INTERNATIONAL JOURNAL OF EATING DISORDERS. 2025; 58(9)DOI:10.1002/eat.24474. PMID:40418102. IF:4.300(Q1/1D).

Cendrós, M, Catalán, R, Torra, M, Penadés, R, González-Rodríguez, A, Brunet, M, Perez-Blanco, J, Cullell, N, Serra-Llovich, A, Hernandez, MH, Arranz, MJ. Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments. PHARMACOPSYCHIATRY. 2025; 58(05)DOI:10.1055/a-2603-0871. PMID:40527340. IF:2.200(Q3/6D).

Camacho-Tellez, V, Castro, MN, De Pino, G, Duarte-Abritta, B, Wainsztein, AE, Herlyn, DL, Goldberg, X, Costanzo, EY, Cordoner, N, Menchón, JM, Soriano-Mas, C, Guinjoan, SM, Villarreal, MF. Occipital structure is linked to vagal tone in borderline personality but not in major depressive disorder. PSYCHIATRY RESEARCH-NEUROIMAGING. 2025; 352DOI:10.1016/j.pscychresns.2025.112044. PMID:40818358. IF:2.100(Q1/1D).

Jessen, F, Arbizu, J, Boada, M, Balasa, M, Bennys, K, Boban, M, Bürger, K, Chincarini, A, Cagnin, A, De Deyn, PP, Düzel, E, Engelborghs, S, Ewers, M, Exalto, LG, van der Flier, WM, Fortea, J, Frederiksen, KS, Frisoni, GB, Frölich, L, Garza-Martinez, AJ, Grimmer, T, Hanseeuw, B, Hort, J, Ivanoiu, A, Kehoe, PG, Kennelly, SP, Kern, S, Klöppel, S, Krajcovicová, L, Kramberger, MG, McGuinness, B, Mecocci, P, Oberstein, TJ, Ousset, PJ, Paquet, C, Perneczky, R, Piazza, F, Plantone, D, Rainero, I, Sacco, G, Salm, E, Santana, I, Scarmeas, N, Schneider, A, Schott, JM, Solje, E, Stefanova, E, Stögmann, E, Strauss, M, Sutovsky, S, Waldemar, G, Winblad, B. Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease. JPAD-Journal of Prevention of Alzheimers Disease. 2025; 12(8)DOI:10.1016/j.tjpad.2025.100259. PMID:40640062. IF:7.800(Q1/1D).